AntiCancer Inc. Has Received a New Patent That Revolutionizes Individualized Mouse Models of Human Cancer Patients by Increasing the Patient-tumor Establishment Rate in Mice to Close to 100%

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, as well as banking their tumors after establishment for future therapy,” said Chihiro Hozumi, co-inventor of the patent and General Manager of AntiCancer’s Japanese subsidiary, AntiCancer Japan.

“The new method is especially important as almost all cancer patients can now have their own individualized clinically-concordant PDOX mouse model,” said AntiCancer Senior Mouse-Model Scientist Jose Reynoso. “The new method facilitates the discovery of effective cancer drugs, since many more mouse models of cancer with patient tumors will be available for testing of novel cancer drugs,” said AntiCancer Senior Scientist Qinghong Han.

AntiCancer Inc. of San Diego was established in 1984 and is celebrating its 40th anniversary. AntiCancer is a world leader in developing individualized cancer therapy, including contract research, using its proprietary PDOX mouse model which it has developed since 1987, and most closely represents the cancer patient.